Remus Pharmaceuticals Limited (NSE:REMUS)

India · Delayed Price · Currency is INR

804.00

-16.50 (-2.01%)

Nov 11, 2026, 1:24 PM IST

Market Cap	9.47B +0.8%
Revenue (ttm)	10.69B +42.9%
Net Income	412.50M +23.1%
EPS	33.78 +23.4%
Shares Out	11.78M
PE Ratio	23.80
Forward PE	n/a
Dividend	1.00 (0.12%)
Ex-Dividend Date	Nov 6, 2026

Volume	4,300
Open	844.00
Previous Close	820.50
Day's Range	798.00 - 850.00
52-Week Range	580.00 - 1,039.00
Beta	0.36
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 3, 2026

About Remus Pharmaceuticals

Remus Pharmaceuticals Limited engages in the marketing, trading, and distribution of pharmaceutical products and allied products in India and internationally. It is involved in trading of active pharmaceutical ingredients, as well as provides technical and consultancy services to various distributors and contract manufacturing services. The company also offers tablet, hard and soft gel capsules, liquid, dry powder, lyophilized injections, as well as pre-filled syringe, infusions, inhalers, nebulizers, nasal sprays, topical sprays, respules, syr... [Read more]

Industry Medical - Pharmaceuticals

Sector Healthcare

Founded 2015

Employees 69

Stock Exchange National Stock Exchange of India

Ticker Symbol REMUS

Full Company Profile

Financial Performance

In fiscal year 2026, Remus Pharmaceuticals's revenue was 8.54 billion, an increase of 37.60% compared to the previous year's 6.20 billion. Earnings were 369.90 million, an increase of 27.24%.

Financial Statements